AGM/EGMApr 28, 2026, 04:33 PM
MAZE to hold 2026 Annual Meeting; Elects 2 Directors, Ratifies Auditor
AI Summary
Maze Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 8, 2026, with a record date of April 13, 2026. Stockholders will vote on the election of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as Class I directors, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026. The board will transition from 10 to 8 members, with Neil Exter and Catherine Angell Sohn not seeking re-election, and new committee appointments planned.
Key Highlights
- Annual Meeting of Stockholders to be held virtually on Monday, June 8, 2026.
- Record date for voting at the Annual Meeting is April 13, 2026.
- Proposes election of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as Class I directors.
- Proposes ratification of Ernst & Young LLP as independent auditor for 2026.
- Board of directors to reduce from 10 to 8 members after the Annual Meeting.
- Neil Exter and Catherine Angell Sohn, Pharm. D. will not stand for re-election.
- Dr. Kumar will join the audit committee following the Annual Meeting.
- Mr. Hoppenot will join and chair the nominating and corporate governance committee post-meeting.
Price Impact
More from MAZE